- Home
- LXRX vs ABSI Comparison
LXRX vs ABSI Comparison
Compare LXRX & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | ABSI |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.6M | 997.8M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LXRX | ABSI |
|---|---|---|
| Price | $2.34 | $7.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.15 | ★ $6.96 |
| AVG Volume (30 Days) | 2.7M | ★ 3.9M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | 10.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,803,000.00 | $4,534,000.00 |
| Revenue This Year | N/A | $215.96 |
| Revenue Next Year | N/A | $319.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $1.02 | $2.24 |
| 52 Week High | $2.68 | $12.06 |
Technical Indicators
Market Signals| Indicator | LXRX | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 33.31 |
| Support Level | $2.04 | $2.56 |
| Resistance Level | $2.61 | $7.06 |
| Average True Range (ATR) | 0.15 | 0.67 |
| MACD | -0.01 | -0.43 |
| Stochastic Oscillator | 65.12 | 4.41 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.